MNPR Monopar Therapeutics Inc.

Monopar Therapeutics, Inc. engages in developing orphan oncology drugs. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

$4.85
As of 11/26/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/19/2019
Outstanding shares:  12,590,612
Average volume:  35,706
Market cap:   $59,301,783
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    61023L108
ISIN:        US61023L1089
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.87
PS ratio:   0.00
Return on equity:   -40.19%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy